Fundraising Fox
Absci
NASDAQ: ABSIUnicorn · $1.4BPortland, US · Founded 2020 · Delaware corporation · 159 employees on LinkedIn · 16 known investors
Find your way into Absci
Each arrow is one introduction. Sign up to fill in the first one.
Ask Max Dawson to introduce you to Shelby Walker
You →Max · together at Dyax →Shelby
Ask Jamie Chen to introduce you to Zachariah Jonasson
You →Jamie · together at Green Theme Technologies →Zachariah
Sign up to find every way you can get introduced to Absci
- Your email: who you already know at Absci, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Absci team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch. It develops drug candidates like ABS-201 for conditions including androgenetic alopecia and applies reverse immunology for novel target discovery.
Founders & leadership
Absci was founded in 2020 by Sean McClain.
Board
Investors · 16
How we know: IKJ Capital's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Phoenix Venture Partners's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Tau Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: stocktitan.net · Not right? Tell us
How we know: the S-1 prospectus · stocktitan.net · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$321M disclosed across 6 rounds · 2016–2026
- $100MraisedJun 2026 · 3 sources
Adage, BVF Partners, Columbia Threadneedle, Eli Lilly & Company, Invus, Redmile
Source ↗
▶$125MraisedMar 2021 · 24 investors · BiotechnologyRule 506(b)
- Andreas PihlDirector
- Gustavo MahlerDirector
- Karen McGinnisDirector
- Ivana Magovcevic-LiebischDirector
- V. Bryan LawlisDirector
- Zach JonassonDirector
- Gregory SchiffmanExecutive Officer
- Sean McClainExecutive Officer, Director
- Eli CasdinDirector
- Amrit NagpalDirector
- Offering amount
- $125M
- Amount sold
- $125M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$70MraisedMar 2021 · 14 investors · BiotechnologyRule 506(b)
- Lawrence McClureExecutive Officer
- Zach JonassonDirector
- Eli CasdinDirector
- Andreas PihlDirector
- Amrit NagpalDirector
- Karen McGinnisDirector
- Gustavo MahlerDirector
- Ivana Magovcevic-LiebischDirector
- V. Bryan LawlisDirector
- Gregory SchiffmanExecutive Officer
- Sean McClainExecutive Officer, Director
- Offering amount
- $70M
- Amount sold
- $70M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$10.4MraisedDec 2019 · 17 investors · BiotechnologyRule 506(b)
- Sean McClainExecutive Officer, Director
- Shelley KlassenExecutive Officer
- Zach JonassonDirector
- Bryan LawlisDirector
- Daniel GoldDirector
- Gustavo MahlerDirector
- Offering amount
- $15M
- Amount sold
- $10.4M
- Minimum investment
- $10K
- Proceeds to insiders
- $1M
- First sale
- Dec 2019
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b, 4a5
▶$12MraisedJun 2018 · 31 investors · BiotechnologyRule 506(b)
- Phil BarishExecutive Officer, Director
- Daniel GoldDirector
- Gustavo MahlerDirector
- Sean McClainExecutive Officer, Director
- Bryan LawlissDirector
- Zach Zach JonassonDirector
- Shelley KlassenExecutive Officer
- Offering amount
- $15M
- Amount sold
- $12M
- Proceeds to insiders
- $500K
- First sale
- May 2018
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b, 4a5
▶$3.7MraisedApr 2016 · 12 investors · BiotechnologyRule 506(b)
- Zach JonassonDirector
- Bryan LawlisDirector
- Phil BarishExecutive Officer
- Daniel GoldDirector
- Sean McClainExecutive Officer
- Offering amount
- $6M
- Amount sold
- $3.7M
- Minimum investment
- $10K
- Proceeds to insiders
- $325K
- First sale
- Apr 2016
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
The Absci mafia →7 people who came through Absci went on to found or lead other companies.
Related companies · 6
Companies working in the same space as Absci.
In the news
Frequently asked questions
- What does Absci do?
- Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch. It develops drug candidates like ABS-201 for conditions including androgenetic alopecia and applies reverse immunology for novel target discovery.
- Who founded Absci?
- Absci was founded by Sean McClain in 2020.
- Who are Absci's investors?
- Absci's investors include Convergent Ventures, Das & Co., IKJ Capital, Oregon Venture Fund, Phoenix Venture Partners, Tachyon Ventures, Tau Ventures, AMD Ventures and 5 more.
- How much funding has Absci raised?
- Absci has disclosed $321M raised across 6 rounds.
- Where is Absci headquartered?
- Absci is headquartered in Portland, US.